The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
Objective tracking data combined with cohort data to drive medicine of the future
A total of five observations for Goa and 17 for Monroe
The Portal BioRRAP will cater to all those seeking regulatory approval for biological research
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
As part of Aarogya Pay, QR codes will be installed at doctors’ clinics that patients can scan to avail instant medical loans at 0% interest and 3/6 EMIs.
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Dxcover announced that it will be presenting new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Subscribe To Our Newsletter & Stay Updated
